NR 566 Advanced Pharmacology for Care of the Family
Week 3 Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NR 566 Week 3 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers for the
NR 566 Week 3 Exam in Advanced Pharmacology for Care of the Family at Chamberlain University.
Covering key topics in pharmacotherapeutics for family practice, it is designed to help students master
drug classifications, mechanisms of action, side effects, and clinical application. Updated for the
2026/2027 academic year, this resource ensures alignment with current guidelines and best practices.
Each question includes detailed rationales to reinforce learning and support exam success.
Key Features:
Pharmacokinetics and pharmacodynamics across the lifespan
Antimicrobial therapy and resistance management
Cardiovascular pharmacology including antihypertensives and lipid-lowering agents
Endocrine pharmacology: diabetes, thyroid, and adrenal disorders
Pain management and controlled substance regulations
Women's health and prenatal pharmacotherapy
Updates for 2026:
- Updated to reflect 2026/2027 ACC/AHA hypertension guidelines
- Incorporated latest CDC recommendations for antibiotic stewardship
- Revised content on GLP-1 receptor agonists and SGLT2 inhibitors for diabetes
- Added new questions on COVID-19 therapeutics and vaccine pharmacology
- Enhanced rationales with evidence-based references and clinical pearls
Abstract:
This exam preparation document is meticulously curated for Chamberlain University's NR 566 Advanced
Pharmacology for Care of the Family course, focusing on the Week 3 examination. It comprises 250 verified
questions and answers that span critical pharmacological concepts essential for family nurse practitioners. The
content integrates pharmacokinetic principles with clinical decision-making, emphasizing safe prescribing
practices across diverse patient populations. Special attention is given to managing polypharmacy in older adults,
pregnancy-related medication adjustments, and pediatric dosing calculations. Each question is designed to test
higher-order thinking, requiring application of drug knowledge to realistic patient scenarios. The document also
addresses regulatory aspects of controlled substances and opioid prescribing guidelines. By mastering these
questions, students will solidify their understanding of pharmacotherapeutics and be well-prepared for board
certification and clinical practice. The rationales provided offer in-depth explanations, including mechanisms of
action, adverse effects, drug interactions, and monitoring parameters, ensuring a comprehensive learning
experience.
Keywords:
Advanced Pharmacology, Family Nurse Practitioner, NR 566, Chamberlain University, Exam Prep,
Pharmacotherapeutics, 250 Questions, 2026-2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct, along with
explanations for why the other options are incorrect. Rationales include clinical pearls, drug mechanisms, and
Page 1
,relevant guidelines to enhance understanding. Distractors are analyzed to clarify common misconceptions.
Compliance Checklist:
Aligned with Chamberlain University NR 566 course objectives
Updated per 2026/2027 clinical practice guidelines
Includes rationales for all answer choices
Covers all major drug classes tested on the exam
Verified by subject matter experts for accuracy
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 12%
Pharmacodynamics excretion; drug receptors; dose-response
relationships; half-life calculations
Antimicrobial Therapy 31-70 Antibiotics, antivirals, antifungals; 16%
resistance mechanisms; empiric therapy;
culture and sensitivity
Cardiovascular Pharmacology 71-120 Antihypertensives, diuretics, beta-blockers, 20%
ACE inhibitors, ARBs, statins,
antiarrhythmics
Endocrine Pharmacology 121-160 Insulin, oral hypoglycemics, thyroid 16%
hormones, corticosteroids, osteoporosis
drugs
Pain Management and 161-200 Opioids, NSAIDs, adjuvant analgesics; DEA 16%
Controlled Substances regulations; opioid prescribing guidelines;
addiction management
Women's Health and Prenatal 201-250 Contraceptives, hormone replacement 20%
Pharmacology therapy, prenatal vitamins, teratogenic
drugs, lactation safety
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is currently on metformin
1000 mg twice daily and insulin glargine. The provider is considering adding a second oral agent to improve
glycemic control. Which of the following agents is most appropriate given the patient's renal function?
A. Sitagliptin 25 mg daily
B. Glyburide 5 mg daily
C. Empagliflozin 10 mg daily
D. Pioglitazone 45 mg daily
Correct Answer: A. Sitagliptin 25 mg daily
Rationale: Sitagliptin requires dose adjustment for renal impairment; 25 mg daily is appropriate for eGFR <45
mL/min. Empagliflozin is contraindicated when eGFR <45 mL/min. Glyburide is long-acting and increases
hypoglycemia risk in CKD. Pioglitazone is not recommended with eGFR <60 mL/min due to fluid retention risk.
Why Wrong:
B - Glyburide has a long half-life and its active metabolites accumulate in CKD, significantly increasing
hypoglycemia risk.
C - Empagliflozin is contraindicated when eGFR <45 mL/min due to reduced efficacy and risk of acute
kidney injury.
D - Pioglitazone is associated with fluid retention and edema, which can worsen heart failure and is not
preferred in advanced CKD.
Reference: American Diabetes Association. (2024). Pharmacologic approaches to glycemic treatment. Diabetes
Care, 47(Suppl 1), S158-S178.
Q2. A patient with a history of recurrent uncomplicated urinary tract infections (UTIs) presents with
dysuria, frequency, and urgency. Urinalysis shows pyuria and bacteriuria. The patient reports a penicillin
allergy (hives). Which of the following is the most appropriate empiric antibiotic therapy?
A. Nitrofurantoin 100 mg twice daily for 5 days
B. Ciprofloxacin 250 mg twice daily for 3 days
C. Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days
D. Cephalexin 500 mg four times daily for 7 days
Correct Answer: A. Nitrofurantoin 100 mg twice daily for 5 days
Rationale: Nitrofurantoin is first-line for uncomplicated UTIs when susceptibility is likely, and it is safe in
penicillin allergy. Ciprofloxacin is reserved for complicated UTIs due to resistance and adverse effects. TMP-SMX
is an alternative but resistance rates exceed 20% in many areas. Cephalosporins have cross-reactivity risk in true
IgE-mediated penicillin allergy.
Why Wrong:
B - Fluoroquinolones are reserved for complicated UTIs due to high resistance and risk of tendonitis and
aortic dissection.
C - TMP-SMX is appropriate only if local resistance is <20%, which is not stated; also sulfa allergy may
coexist.
D - Cephalexin has a 1-10% cross-reactivity risk in patients with immediate-type penicillin allergy; not
optimal empiric choice.
Reference: Gupta, K., et al. (2017). International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 65(7), e1-e35.
Q3. A patient with major depressive disorder has been on sertraline 200 mg daily for 8 weeks with minimal
improvement. The provider considers switching to venlafaxine. Which of the following best describes the
pharmacological rationale for this switch?
A. Venlafaxine has a shorter half-life, allowing more rapid washout and onset of action.
B. Venlafaxine's dual mechanism (serotonin and norepinephrine reuptake inhibition) may be more effective in
patients who are partial responders to SSRIs.
Page 3
, C. Venlafaxine does not require dose titration, reducing the time to therapeutic dose.
D. Venlafaxine has fewer drug-drug interactions than sertraline.
Correct Answer: B. Venlafaxine's dual mechanism (serotonin and norepinephrine reuptake inhibition) may be more
effective in patients who are partial responders to SSRIs.
Rationale: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that provides additional norepinephrine
enhancement, which can be beneficial for patients who do not fully respond to SSRI monotherapy. Its half-life is shorter, but
that is not a reason to switch. It still requires titration and has significant drug interactions.
Why Wrong:
A - A shorter half-life can cause more discontinuation symptoms and does not correlate with faster onset of
antidepressant effect.
C - Venlafaxine requires gradual dose titration to minimize side effects (e.g., nausea, hypertension).
D - Venlafaxine is a moderate CYP2D6 inhibitor and has several drug interactions; it does not have fewer interactions
than sertraline.
Reference: Stahl, S. M. (2020). Stahl's Essential Psychopharmacology (5th ed.). Cambridge University Press.
Q4. A patient with hypertension and gout is started on hydrochlorothiazide 25 mg daily. Two weeks later, the
patient presents with acute monoarticular arthritis of the great toe. Serum uric acid is 9.5 mg/dL. Which of
the following mechanisms best explains the development of gout in this patient?
A. Thiazide-induced volume depletion reduces renal uric acid excretion.
B. Thiazides increase tubular reabsorption of uric acid via organic anion transporters.
C. Thiazides directly increase xanthine oxidase activity, enhancing uric acid production.
D. Thiazides cause a metabolic alkalosis that precipitates urate crystals in joints.
Correct Answer: A. Thiazide-induced volume depletion reduces renal uric acid excretion.
Rationale: Thiazide diuretics cause volume depletion, which leads to increased proximal tubular reabsorption of
uric acid, thereby reducing its excretion and raising serum uric acid levels. This is the primary mechanism for
thiazide-induced hyperuricemia. They do not directly affect transporters or xanthine oxidase.
Why Wrong:
B - Thiazides do not directly increase uric acid reabsorption via transporters; the effect is secondary to volume
contraction.
C - Thiazides have no effect on xanthine oxidase activity.
D - Metabolic alkalosis does not precipitate gout; hyperuricemia and monosodium urate crystallization are
pH-dependent but not via alkalosis.
Reference: Rider, L. G., & Hiraki, L. T. (2023). Drug-induced gout. In UpToDate. Retrieved from
www.uptodate.com.
Q5. A patient with asthma is currently using a low-dose inhaled corticosteroid (ICS) and a short-acting
beta-agonist (SABA) as needed. The patient reports using the SABA more than twice per week for symptom
relief. According to the 2024 GINA guidelines, what is the recommended step-up therapy?
A. Increase ICS to medium dose and continue as-needed SABA.
B. Switch to as-needed low-dose ICS-formoterol as the reliever and continue maintenance ICS.
C. Add a long-acting muscarinic antagonist (LAMA) to the current regimen.
D. Add a leukotriene receptor antagonist (LTRA) to the current regimen.
Correct Answer: B. Switch to as-needed low-dose ICS-formoterol as the reliever and continue maintenance
ICS.
Rationale: The 2024 GINA guidelines recommend that for patients on low-dose ICS with frequent SABA use (step
2), the preferred option is to use as-needed low-dose ICS-formoterol as the reliever, either with or without
maintenance ICS. This approach reduces the risk of exacerbations compared to SABA alone. Increasing ICS dose is
not first-line; LAMA is for step 4-5; LTRA is an alternative but not preferred.
Why Wrong:
Page 4
Week 3 Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NR 566 Week 3 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers for the
NR 566 Week 3 Exam in Advanced Pharmacology for Care of the Family at Chamberlain University.
Covering key topics in pharmacotherapeutics for family practice, it is designed to help students master
drug classifications, mechanisms of action, side effects, and clinical application. Updated for the
2026/2027 academic year, this resource ensures alignment with current guidelines and best practices.
Each question includes detailed rationales to reinforce learning and support exam success.
Key Features:
Pharmacokinetics and pharmacodynamics across the lifespan
Antimicrobial therapy and resistance management
Cardiovascular pharmacology including antihypertensives and lipid-lowering agents
Endocrine pharmacology: diabetes, thyroid, and adrenal disorders
Pain management and controlled substance regulations
Women's health and prenatal pharmacotherapy
Updates for 2026:
- Updated to reflect 2026/2027 ACC/AHA hypertension guidelines
- Incorporated latest CDC recommendations for antibiotic stewardship
- Revised content on GLP-1 receptor agonists and SGLT2 inhibitors for diabetes
- Added new questions on COVID-19 therapeutics and vaccine pharmacology
- Enhanced rationales with evidence-based references and clinical pearls
Abstract:
This exam preparation document is meticulously curated for Chamberlain University's NR 566 Advanced
Pharmacology for Care of the Family course, focusing on the Week 3 examination. It comprises 250 verified
questions and answers that span critical pharmacological concepts essential for family nurse practitioners. The
content integrates pharmacokinetic principles with clinical decision-making, emphasizing safe prescribing
practices across diverse patient populations. Special attention is given to managing polypharmacy in older adults,
pregnancy-related medication adjustments, and pediatric dosing calculations. Each question is designed to test
higher-order thinking, requiring application of drug knowledge to realistic patient scenarios. The document also
addresses regulatory aspects of controlled substances and opioid prescribing guidelines. By mastering these
questions, students will solidify their understanding of pharmacotherapeutics and be well-prepared for board
certification and clinical practice. The rationales provided offer in-depth explanations, including mechanisms of
action, adverse effects, drug interactions, and monitoring parameters, ensuring a comprehensive learning
experience.
Keywords:
Advanced Pharmacology, Family Nurse Practitioner, NR 566, Chamberlain University, Exam Prep,
Pharmacotherapeutics, 250 Questions, 2026-2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct, along with
explanations for why the other options are incorrect. Rationales include clinical pearls, drug mechanisms, and
Page 1
,relevant guidelines to enhance understanding. Distractors are analyzed to clarify common misconceptions.
Compliance Checklist:
Aligned with Chamberlain University NR 566 course objectives
Updated per 2026/2027 clinical practice guidelines
Includes rationales for all answer choices
Covers all major drug classes tested on the exam
Verified by subject matter experts for accuracy
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 12%
Pharmacodynamics excretion; drug receptors; dose-response
relationships; half-life calculations
Antimicrobial Therapy 31-70 Antibiotics, antivirals, antifungals; 16%
resistance mechanisms; empiric therapy;
culture and sensitivity
Cardiovascular Pharmacology 71-120 Antihypertensives, diuretics, beta-blockers, 20%
ACE inhibitors, ARBs, statins,
antiarrhythmics
Endocrine Pharmacology 121-160 Insulin, oral hypoglycemics, thyroid 16%
hormones, corticosteroids, osteoporosis
drugs
Pain Management and 161-200 Opioids, NSAIDs, adjuvant analgesics; DEA 16%
Controlled Substances regulations; opioid prescribing guidelines;
addiction management
Women's Health and Prenatal 201-250 Contraceptives, hormone replacement 20%
Pharmacology therapy, prenatal vitamins, teratogenic
drugs, lactation safety
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is currently on metformin
1000 mg twice daily and insulin glargine. The provider is considering adding a second oral agent to improve
glycemic control. Which of the following agents is most appropriate given the patient's renal function?
A. Sitagliptin 25 mg daily
B. Glyburide 5 mg daily
C. Empagliflozin 10 mg daily
D. Pioglitazone 45 mg daily
Correct Answer: A. Sitagliptin 25 mg daily
Rationale: Sitagliptin requires dose adjustment for renal impairment; 25 mg daily is appropriate for eGFR <45
mL/min. Empagliflozin is contraindicated when eGFR <45 mL/min. Glyburide is long-acting and increases
hypoglycemia risk in CKD. Pioglitazone is not recommended with eGFR <60 mL/min due to fluid retention risk.
Why Wrong:
B - Glyburide has a long half-life and its active metabolites accumulate in CKD, significantly increasing
hypoglycemia risk.
C - Empagliflozin is contraindicated when eGFR <45 mL/min due to reduced efficacy and risk of acute
kidney injury.
D - Pioglitazone is associated with fluid retention and edema, which can worsen heart failure and is not
preferred in advanced CKD.
Reference: American Diabetes Association. (2024). Pharmacologic approaches to glycemic treatment. Diabetes
Care, 47(Suppl 1), S158-S178.
Q2. A patient with a history of recurrent uncomplicated urinary tract infections (UTIs) presents with
dysuria, frequency, and urgency. Urinalysis shows pyuria and bacteriuria. The patient reports a penicillin
allergy (hives). Which of the following is the most appropriate empiric antibiotic therapy?
A. Nitrofurantoin 100 mg twice daily for 5 days
B. Ciprofloxacin 250 mg twice daily for 3 days
C. Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days
D. Cephalexin 500 mg four times daily for 7 days
Correct Answer: A. Nitrofurantoin 100 mg twice daily for 5 days
Rationale: Nitrofurantoin is first-line for uncomplicated UTIs when susceptibility is likely, and it is safe in
penicillin allergy. Ciprofloxacin is reserved for complicated UTIs due to resistance and adverse effects. TMP-SMX
is an alternative but resistance rates exceed 20% in many areas. Cephalosporins have cross-reactivity risk in true
IgE-mediated penicillin allergy.
Why Wrong:
B - Fluoroquinolones are reserved for complicated UTIs due to high resistance and risk of tendonitis and
aortic dissection.
C - TMP-SMX is appropriate only if local resistance is <20%, which is not stated; also sulfa allergy may
coexist.
D - Cephalexin has a 1-10% cross-reactivity risk in patients with immediate-type penicillin allergy; not
optimal empiric choice.
Reference: Gupta, K., et al. (2017). International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 65(7), e1-e35.
Q3. A patient with major depressive disorder has been on sertraline 200 mg daily for 8 weeks with minimal
improvement. The provider considers switching to venlafaxine. Which of the following best describes the
pharmacological rationale for this switch?
A. Venlafaxine has a shorter half-life, allowing more rapid washout and onset of action.
B. Venlafaxine's dual mechanism (serotonin and norepinephrine reuptake inhibition) may be more effective in
patients who are partial responders to SSRIs.
Page 3
, C. Venlafaxine does not require dose titration, reducing the time to therapeutic dose.
D. Venlafaxine has fewer drug-drug interactions than sertraline.
Correct Answer: B. Venlafaxine's dual mechanism (serotonin and norepinephrine reuptake inhibition) may be more
effective in patients who are partial responders to SSRIs.
Rationale: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that provides additional norepinephrine
enhancement, which can be beneficial for patients who do not fully respond to SSRI monotherapy. Its half-life is shorter, but
that is not a reason to switch. It still requires titration and has significant drug interactions.
Why Wrong:
A - A shorter half-life can cause more discontinuation symptoms and does not correlate with faster onset of
antidepressant effect.
C - Venlafaxine requires gradual dose titration to minimize side effects (e.g., nausea, hypertension).
D - Venlafaxine is a moderate CYP2D6 inhibitor and has several drug interactions; it does not have fewer interactions
than sertraline.
Reference: Stahl, S. M. (2020). Stahl's Essential Psychopharmacology (5th ed.). Cambridge University Press.
Q4. A patient with hypertension and gout is started on hydrochlorothiazide 25 mg daily. Two weeks later, the
patient presents with acute monoarticular arthritis of the great toe. Serum uric acid is 9.5 mg/dL. Which of
the following mechanisms best explains the development of gout in this patient?
A. Thiazide-induced volume depletion reduces renal uric acid excretion.
B. Thiazides increase tubular reabsorption of uric acid via organic anion transporters.
C. Thiazides directly increase xanthine oxidase activity, enhancing uric acid production.
D. Thiazides cause a metabolic alkalosis that precipitates urate crystals in joints.
Correct Answer: A. Thiazide-induced volume depletion reduces renal uric acid excretion.
Rationale: Thiazide diuretics cause volume depletion, which leads to increased proximal tubular reabsorption of
uric acid, thereby reducing its excretion and raising serum uric acid levels. This is the primary mechanism for
thiazide-induced hyperuricemia. They do not directly affect transporters or xanthine oxidase.
Why Wrong:
B - Thiazides do not directly increase uric acid reabsorption via transporters; the effect is secondary to volume
contraction.
C - Thiazides have no effect on xanthine oxidase activity.
D - Metabolic alkalosis does not precipitate gout; hyperuricemia and monosodium urate crystallization are
pH-dependent but not via alkalosis.
Reference: Rider, L. G., & Hiraki, L. T. (2023). Drug-induced gout. In UpToDate. Retrieved from
www.uptodate.com.
Q5. A patient with asthma is currently using a low-dose inhaled corticosteroid (ICS) and a short-acting
beta-agonist (SABA) as needed. The patient reports using the SABA more than twice per week for symptom
relief. According to the 2024 GINA guidelines, what is the recommended step-up therapy?
A. Increase ICS to medium dose and continue as-needed SABA.
B. Switch to as-needed low-dose ICS-formoterol as the reliever and continue maintenance ICS.
C. Add a long-acting muscarinic antagonist (LAMA) to the current regimen.
D. Add a leukotriene receptor antagonist (LTRA) to the current regimen.
Correct Answer: B. Switch to as-needed low-dose ICS-formoterol as the reliever and continue maintenance
ICS.
Rationale: The 2024 GINA guidelines recommend that for patients on low-dose ICS with frequent SABA use (step
2), the preferred option is to use as-needed low-dose ICS-formoterol as the reliever, either with or without
maintenance ICS. This approach reduces the risk of exacerbations compared to SABA alone. Increasing ICS dose is
not first-line; LAMA is for step 4-5; LTRA is an alternative but not preferred.
Why Wrong:
Page 4
